Kazia Therapeutics annual r&d spending
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Kazia Therapeutics R&D Spending Growth & History (KZIA)
Kazia Therapeutics's r&d spending was $7.3M for fiscal 2025.
View full Kazia Therapeutics company overviewKazia Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | $7.3M | −$10.1M | −57.85% |
| 2024 | 2024-06-30 | $17.4M | $1.8M | +11.67% |
| 2023 | 2023-06-30 | $15.6M | −$4.6M | −22.83% |
| 2022 | 2022-06-30 | $20.2M | $5.6M | +38.70% |
| 2021 | 2021-06-30 | $14.5M | $5.0M | +53.16% |
| 2020 | 2020-06-30 | $9.5M | $3.0M | +46.63% |
| 2019 | 2019-06-30 | $6.5M | −$3.3M | −33.75% |
| 2018 | 2018-06-30 | $9.8M | −$1.4M | −12.23% |
| 2017 | 2017-06-30 | $11.1M | $1.2M | +12.55% |
| 2016 | 2016-06-30 | $9.9M | — | — |
Kazia Therapeutics r&d spending trends
Over the last five fiscal years, Kazia Therapeutics's r&d spending decreased from $9.5M to $7.3M, a change of −$2.2M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kazia Therapeutics source filings ↗